Some of Advanced NMR's shareholders are not pleased with the company'splan to acquire the remaining shares outstanding of subsidiaryAdvanced Mammography Systems (SCAN 2/14/96). The Wilmington, MA,company announced last week that a class action lawsuit
Some of Advanced NMR's shareholders are not pleased with the company'splan to acquire the remaining shares outstanding of subsidiaryAdvanced Mammography Systems (SCAN 2/14/96). The Wilmington, MA,company announced last week that a class action lawsuit has beenfiled against it by shareholders who claim that the terms of thetransaction are unfair.
Advanced NMR now owns 61% of Advanced Mammography Systems andintends to acquire 100% of the MR mammography developer underthe buyout plan. The company said that it is preparing proxy materialsfor the merger, which will be proposed to AMS shareholders ata meeting to be held in late spring. It said that it believesthe terms of the acquisition are fair.
ANMR this month also released financial results for the firstquarter of 1996 (end-December) that show the positive contributionbeing made by Medical Diagnostics, which ANMR acquired last August(SCAN 5/10/95).
ANMR had revenues for the quarter of $6.2 million, of whichAdvanced NMR system sales contributed only $49,000 while the restcame from MDI's imaging services business. ANMR had a net lossof $1.6 million, compared with a net loss of $2.2 million in thesame quarter last year. The MDI business was profitable. ANMRexpects system sales to increase, as the company has a $4.8 millionbacklog, according to chairman and CEO Jack Nelson.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
2 Commerce Drive
Cranbury, NJ 08512